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The aim of the present study was to investigate homoharringtonine alkaloid effect on: (i) the nonenzymatic and eEF-l-dependent Phe-tRNAPhc 
binding to poly(U)-programmed human placenta 80 S ribosomes; (ii) diphenylalanine synthesis accompanying nonenzymatic Phe-tRNAPhC binding; 
and (iii) acetylphenylalanyl-puromycin formation. Neither nonenzymatic nor eEF-l-dependent Phe-tRNAPhe binding were noticeably affected by 
the alkaloid, whereas diphenylalanine synthesis and puromycin reaction were strongly inhibited by homoharringtonine. It has been proposed that 
the site of homoharringtonine binding on 80 S ribosomes should overlap or coincide with the acceptor site of the ribosome. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
Homoharringtonine and related alkaloids from Poly(LJ) was purchased from Reanal (Hungary); puromycin from Fluka; [“‘C]phenylalanine (318 Ci/mol) from UVVVR 
(Czechoslovakia). Enriched [‘4C]Phe-tRNAPhe (1400 pmol/A2ba 
unit) and Ac-Phe-tRNAPhC from E. co/i-MRE-600 were prepared as 
in [5,6]. eEF-lcu from the rabbit liver was kindly given to us by Dr 
S. Tuhachkova. Human placenta ribosomal subunits were prepared 
as described previously [7]. The subunits were reactivated for 10 min 
at 37°C in TKM buffer (13 mM MgC12, 0.6 mM EDTA, 120 mM 
KCl, 20 mM Tris-HCI, pH 7.5), mixed in the molar ratio of 
40 S: 60 S as 1: 1.3. 1 Aa60 unit was assumed to be 50 pmol of 40 S 
and 25 pmol of 60 S subunits [8]. Poly(U)-dependent nonenzymatic 
binding of [‘?J]Phe-tRNAPhe (7 x lo-’ M, if not indicated other- 
wise) to 80 S ribosomes (1.65 x lo-’ M) was carried out in TKM buf- 
fer for 40 min at 0°C. Diphenylalanine formation was checked as in 
[9]. eEF-l-dependent [‘4C]Phe-tRNAPhe binding to 80 S ribosomes 
was performed in two steps. First, 7 pmol of 80 S ribosomes were in- 
cubated with 0.6 4260 unit of E. coli tRNA and 0.2 Asea unit of po- 
ly(U) for 5 min at 37°C in TKM buffer to block ribosomal P site. 
Second, a ternary complex was obtained by incubation of 4pg of 
eEF-lcu, 9 pmol of Phe-tRNAPhe and 6 nmol of GTP in buffer 
(100 mM KCl, 3 mM MgC12, 20 mM Tris-HC1, pH 7.5) at 0°C for 
15 min. These two complexes were mixed and incubated at 0°C for 
15 min. Phe-tRNAPhe binding was tested using nitrocellulose filtra- 
tion technique. Puromycin reaction was performed according to [IO]. 
Cephalotaxus harringtonia are known to be inhibitors 
of protein biosynthesis in some eukaryotic cells. It has 
been initially proposed that these compounds inhibit in- 
itiation in intact cells and cell lysates [ 1,2]. Further in- 
vestigations clearly showed that such an effect was due 
to the prevention of the elongation cycle in contradic- 
tion to the previous proposals [3,4]. The results 
presented in the above-mentioned works suggested that 
Cephalotaxus alkaloids inhibited not only peptide bond 
formation in the fragment reaction assays but also en- 
zymatic and non-enzymatic binding of the Phe- 
tRNAPhe to ribosomes. In spite of being widely used in 
medicine as antitumour agents these compounds, 
however, have hardly been applied to research practice 
so far, since the mechanism of their action was not 
clear. Thus, it seems worthwhile investigating the 
mechanism of their inhibition of protein synthesis in 
eukaryotic systems, especially in human cells. 
In the present paper we have studied an effect of 
homoharringtonine on: (i) nonenzymatic binding of in- 
dividual Phe-tRNAPhe simultaneously at A and P sites 
of poly(U)-programmed 80 S ribosomes from human 
placenta and diphenylalanine synthesis under these 
conditions; (ii) eEF 1 -dependent Phe-tRNAPh’ binding 
at the ribosomal A site; and (iii) acetylphenylalanyl- 
puromycin formation under treatment of the complex 
80 S AcPhe-tRNAPh’ poly(U) with puromycin. 
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Homoharringtonine (Sigma) was converted to the HCl-form and 
dissolved in the TKM buffer. It was used in concentration 10e4 M in 
reaction mixtures; the ribosomes were preincubated with the alkaloid 
in the same concentration (unless otherwise specified) at 2O”C, for 
10 min. 
3. RESULTS AND DISCUSSION 
Binding capacity of poly(U)-programmed 80 S 
ribosomes was tested by their titration with [14C]Phe- 
tRNAPhe in the absence of translation factors (fig.1). 
Under the conditions of ribosomal saturation with Phe- 
tRNAPhe, the amount of diphenylalanine formed was 
analysed (see table 1). 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
254 00145793/89/$3.50 Q 1989 Federation of European Biochemical Societies 
Volume 251, number 2 FEBS LETTERS November 1989 
Phe-tRNAPhe 1805 
Fig.1. Titration of human placenta 80 S ribosomes with [?Z]Phe- 
tRNAPhe. (0) With poly(U); (0) without poly(U). 
It is seen that the maximum level of poly(U)-directed 
Phe-tRNA binding is about 0.7 mol/mol of 80 S 
ribosomes (fig. 1). From the data presented in table 1 it 
is evident that most parts of the Phe residues bound to 
the ribosomes participated in (Phe)z formation. So, the 
majority of active ribosomes bound Phe-tRNAPhe 
simultaneously at A and P sites and about 35% of the 
ribosomes were active in this binding. At a concentra- 
tion of 10m4 M homoharringtonine does not 
significantly affect nonenzymatic Phe-tRNAPhe bin- 
ding to 80 S ribosomes, but almost completely inhibits 
transpeptidation (diphenylalanine formation, see table 
1). The alkaloid slightly affects not only nonenzymatic 
but also eEF-la dependent Phe-tRNAPhe binding (see 
table 1). 
We have also studied inhibitory action of homoharr- 
ingtonine on acetylphenylalanyl-puromycin formation 
when complex 80 S poly(U) Ac[14C]Phe-tRNAPhe was 
treated with puromycin. The complex was obtained at 
relatively low AcPhe-tRNAPhe concentration; earlier in 
the same system on E. coli ribosomes it was shown that 
under such conditions, binding was preferable at the 
puromycin-reactive P site [I 11. As can be seen from 
fig.2, AcPhe-puromycin formation is strongly inhibited 
in the case where homoharringtonine has been added to 
the complex 80 S poly(U) AcPhe-tRNAPhe upon the ad- 
Table 1 
Homoharringtonine effect on: (i) nonenzymatic [%]Phe-tRNA 
binding to poly(U)-programmed 80 S ribosomes from human 
placenta and diphenylalanine synthesis; and (ii) eEF-l-dependent 
[14C]Phe-tRNA binding to the ribosomal P site 
Ribosomes Nonenzymatic 
binding 
Binding level Phe synthesis 
(mol Phe- (mol Phe/ 
tRNA/mol mol ribo- 
ribosomes) somes) 
eEF-l-dependent 
binding 
With Without 
eEF-1 eEF-1 
Untreated 0.70 0.30 0.30 0.05 
Preincubated 0.56 0.02 0.24 0.05 
;: 024 
m 
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Fig.2. Kinetics of acetyl [‘4C]phenylalanyl-puromycin formation 
(.)9 without homoharringtonine; (0) 80 S ribosomes were 
preincubated with the alkaloid; (A) homoharringtonine was added to 
the reaction mixture 10 min after puromycin addition (indicated with 
arrow). Binding of Ac[‘4C]Phe-tRNAPhe (1.6 x lo-’ M) to the 80 S 
ribosomes (1.6 x lo-’ M) and poly(U) (5 AZ60 units/ml) was carried 
out by incubation of the components in the TM buffer at 20°C for 
20 min. The binding level of AcPhe-tRNAPhC was about 
0.25 mol/mol ribosomes. Puromycin treatment of the complex was 
performed at 37°C for 10 min. 
dition of puromycin and is almost completely inhibited 
in the case where 80 S ribosomes have been prein- 
cubated with the alkaloid before the complex for- 
mation. 
So, homoharringtonine selectively inhibits peptide 
bond formation and almost does not hinder codon- 
dependent tRNAPhe binding both nonenzymatically 
and eEF-l-dependently at ribosomal A and P sites. 
Since, the alkaloid inhibits AcPhe-puromycin forma- 
tion independently of time of addition, one may sug- 
gest that the site of homoharringtonine binding should 
overlap or coincide with the acceptor site of the pep- 
tidy1 transferase centre of ribosomes from human 
placenta. 
The obtained data differ from the results reported 
earlier on ribosomes from rabbit reticulocytes [3]. Ac- 
cording to [3], Cephalotuxus alkaloids prevent not only 
transpeptidation but also tRNA binding to ribosomes 
(both nonenzymatic and enzymatic). Probably, the 
mechanism of the alkaloids’ inhibitory action depends 
on the source of ribosomes. But it is more reasonable 
to suggest hat the observed differences should be due 
to different ways of alkaloid dissolution: in [3] it was 
dissolved in the form of a base in dimethyl sulfoxide 
and this solution was added to ribosomes, while in the 
present paper, homoharringtonine was converted into 
the HCl form in aqueous solution. 
There is no set of antibiotics selectively inhibiting 
definite steps of the eukaryotic elongation cycle in con- 
trast to prokaryotic one. Therefore homoharringtonine 
may be useful as a selective inhibitor of transpeptida- 
tion in the studies of different states of tRNA on 
ribosomes in different model systems imitating various 
steps of the elongation cycle. 
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